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Abstract Rheumatoid arthritis (RA) is a chronic inflam-
matory autoimmune disorder resulting in the erosion of the
cartilage and bone. Systemic involvement including the
cardiovascular system with the risk of atherosclerosis may
also occur. Calibrated automated thrombogram (CAT), a
commercially available thrombin generation assay is suit-
able for the general assessment of the functionality of
coagulation system. In this study we performed CAT assay
in RA patients and in non-affected control subjects (mat-
ched for age, sex and comorbidities). Among the CAT
parameters Velocity Index increased (from 60 to 83 nM/
min), Lag Time and Time to Peak decreased (from 3.47 to
2.83 min and from 6.98 to 5.58 min respectively) in RA.
On the other hand, Endogenous Thrombin Potential values
decreased (from 1242 to 1108 nM min). The observed
alterations were not associated with the applied therapy.
These results indicate that the velocity of thrombin for-
mation is increased, while the thrombin generating capa-
bility is reduced in RA.
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Abbreviations
aPTT Activated partial thromboplastin time
CAT Calibrated Automated Thrombogram
CRP C reactive protein
DAS Disease activity score
DMARD Disease modifying anti-rheumatic drugs
ESR Erythrocyte sedimentation rate
ETP Endogenous thrombin potential
NSAID Non-steroidal anti-inflammatory drugs
PT Prothrombin time
RA Rheumatoid arthritis
RF Rheumatoid factor
TG Thrombin generation
TT Thrombin time
v index Velocity Index
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory autoim-
munedisorderwith a symmetrical small-joint polyarthritis, but
extra-articular manifestations may be present both at disease
onset and in established disease. There are a number of studies
indicating the augmented risk of cardiovascular diseases inRA
including atherothrombosis [1, 2] and venous thromboem-
bolism [3, 4].However, from the limited data available it is still
nebulous whether the increased risk is inherent with RA itself
or is partly due to potential confounders [3]. Indeed, in addition
to the thrombogenic effects of systemic inflammation,
immobilisation, plasma hyperviscosity [5], disturbed venous
blood flow [6] and adverse effects of anti-rheumatic agents [7]
may also contribute to the thrombotic tendency in RA.
Beside standard coagulation tests [prothrombin time
(PT), activated partial thromboplastin time (aPTT),
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thrombin time (TT) and fibrinogen] novel biomarkers in
the assessment of thrombotic potential have been recently
introduced into the laboratory diagnostic arsenal. Thrombin
generation (TG) test, a novel global haemostasis assay, is a
tool for the general functional assessment of haemostasis.
The result of this test reflects reliably thrombotic or
bleeding potential that can be triggered by physiologic or
iatrogenic stimuli [8]. During TG test coagulation is pro-
voked in the plasma sample by the addition of a small
amount of triggering agent (usually thromboplastin). The
activity of thrombin is monitored during the entire coagu-
lation process and graphically represented on the throm-
bogram (Fig. 1). TG profile is characterised by descriptive
parameters of the TG curve: Endogenous Thrombin
Potential (ETP, total thrombin generating potential of the
sample), Peak (maximum thrombin activity), Lag Time
(initiation time to thrombin burst), Time to Peak (time to
maximum thrombin activity) and Velocity Index (v index,
slope of the thrombin burst).
Albeit TG measurements are still not standardized,
commercially available tests are already in use. Calibrated
automated thrombogram (CAT) is one of the most widely
used TG assays. CAT is increasingly used to assess
thrombotic risk in a number of disorders including cancer
[9], or anticoagulant treatment [10].
Until now only two studies assessed TG in RA. Undas
et al. however, collected indirect data regarding TG; they
developed an in silico model and estimated TG profile by
analysing a number of distinct soluble pro- and anticoag-
ulant factors in patients [11]. Their results indicate delayed
but augmented thrombin burst in RA samples. However,
this study was inherent with several limitations (e.g. the
control group consisted of healthy subjects instead of non-
affected controls and study population was heterogeneous
in term of age and gender). In a more recent study Prati
et al. empirically determined the TG profiles in RA [12].
They detected alteration in all TG parameters suggesting a
reduced TG in RA (indicative for an increased bleeding
tendency), but no data about the study population and the
applied method are provided.
In this study we aimed to evaluate TG parameters in a
well-defined and homogeneous RA population and inves-
tigated the impact of RA and applied therapy on measured
values.
Patients and methods
Patients
Twenty-four and 25 postmenopausal women with and
without RA, respectively, matched for age and comor-
bidities were included in the study. RA patients and control
subjects (with joint complaints, but no inflammatory con-
dition) were recruited from the same department. Exclusion
criteria were oral anticoagulant therapy or heparin therapy.
Patients were treated with corticosteroids (n = 14,
58.3 %), nonsteroidal anti-inflammatory drugs (NSAIDs,
n = 5, 20.8 %), biologic agents (n = 10, 41.7 %), disease
modifying antirheumatic drugs (DMARDs, n = 22,
91.7 %) and statins (n = 5, 20.8 %). None of the control
subjects were treated with corticosteroids, DMARDs and
biologic agents. Disease activity score (DAS-28) was cal-
culated for all patients at the time of sampling. Level of
standard inflammatory markers [C reactive protein (CRP),
erythrocyte sedimentation rate (ESR)] and that of
rheumatoid factor (RF) and anti mutated citrullinate
vimentin (aMCV) were measured parallel (Table 1).
Patients and subjects gave written informed consent to
participate in the study. The study adhered to the tenets of
declaration of Helsinki.
Methods
Venous blood samples were drawn in Vacutainer tubes
(Becton–Dickinson, USA) containing 3.2 % sodium
Fig. 1 Thrombogram, graphical representation of a thrombin gener-
ation (TG) measurement. a Parameters of thrombogram. b Character-
istic alterations of thrombogram in thrombophilia and haemophilia.
Augmented peak, ETP and v index, and decreased Lag Time and
Time to Peak suggest an increase in thrombotic tendency, while
reduced peak, ETP and v index, and prolonged Lag Time and Time to
Peak indicate an increase in bleeding tendency
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citrate. For standard coagulation tests (see below) the
samples were centrifuged at 25009g for 10 min. To obtain
platelet poor plasma (PPP) for the TG measurement the
samples were centrifuged first at 25009g for 10 min, then
at 25009g for 20 min. Samples were immediately frozen
and stored at -80 C until measurements (done within
1 month).
Standard coagulation parameters (PT, aPTT, TT and
fibrinogen) were determined with reagents from Diagon
(Hungary) on Coag XL automated coagulometer (Diagon,
Hungary).
CAT method (Diagnostica Stago, France) was per-
formed by applying PPP Reagent (Thrombinoscope, The
Netherlands). Briefly, 80 ll plasma sample was mixed with
20 ll trigger (PPP Reagent, Thrombinoscope, The
Netherlands) in 96 round bottom wells micro plate (Im-
mulon 2HB, Thermo Fisher Scientific, USA). The mea-
surement was started by the addition of 40 ll mixture
containing CaCl2 and fluorogenic substrate (FluCA-kit,
Thrombinoscope, The Netherlands). All samples were run
in duplicate at 37 C. Each plasma sample was calibrated
individually by applying Thrombin Calibrator (Throm-
binoscope, The Netherlands) in order to correct the
fluorescent signal for inner filter effect, substrate con-
sumption and variability in colour of plasma. Fluorescence
was measured with Fluoroskan Ascent (Thermo Fisher
Scientific, USA) reader applying 390 nm excitation and
460 nm emission filters. TG parameters were calculated
with Thrombinoscope Software (Thrombinoscope, The
Netherlands). The following TG parameters were deter-
mined: Endogenous Thrombin Potential (ETP, nM min),
Peak (nM), Lag Time (min), Time to Peak (min) and
Velocity Index (v index, nM/min).
Statistical analysis
Normal distribution of data was analysed with Anderson–
Darling normality test. Qualitative data are expressed as
number (%) and quantitative data as mean ± standard
deviation or median (1st–3rd interquartile), as appropri-
ate. Coagulation parameters were compared between RA
and non-affected control group, and between RA patients
receiving standard, or standard and biological therapy.
Comparison between groups was performed with Student
t-test in case of normal distribution or with Mann–
Whitney U test in case of non-normal distribution.
Coagulation parameters of RA patients were correlated
with age, disease duration, DAS-28, CRP, ESR and RF.
Correlations were assessed with Pearson or Spearman
rank coefficient, as appropriate. All tests were two sided,
and p values \0.05 were considered statistically signifi-
cant. Statistical analyses were performed with Minitab 
Release 14.1.
Results
Twenty-four patients and 25 control subjects were enrolled
into the study. RA patients had significantly higher TT,
although the values were within the normal range and the
difference was clinically irrelevant. PT, aPTT and fib-
rinogen levels were not statistically different. On the other
hand, several CAT parameters differed significantly
between RA and control group; Lag Time, Time to Peak
and ETP were lower, while v index were higher in RA than
in control group (Table 2).
None of the standard coagulation parameters were
associated with age, RA duration, RF, aMCV or ESR
values in the RA group. Within RA group, fibrinogen
levels correlated with DAS-28 (r = 0.680, p\ 0.0005) and
with CRP (q = 0.663, p = 0.001). DAS-28 also correlated
with Lag Time (q = 0.438, p = 0.032) and v index
(q = 0.526, p = 0.008). No difference was observed in RA
subgroups receiving DMARDs and those on combination
with DMARD and biologic agent.
Table 1 Clinical characteristics of patients with RA and controls
studied
Patient Control
Number 24 25
Age (years) 61.7 ± 7.5 56.5 ± 10.8
Duration of RA (years) 11.8 ± 8.8 –
DAS-28 3.29 ± 1.41 –
CRP (mg/l) 5.0 (3.2–11.4) (n = 23) 2.3 (0–4.5)
ESR (mm/h) 26 (12–52) (n = 21) –
RF (IU/ml) 101.4 (34.9–404.3) (n = 21) –
aMCV 19 (79.2 %) –
Diabetes mellitus 3 (12.5 %) 3 (12.0 %)
Hypothyreosis 6 (25.0 %) 4 (16.0 %)
Hypertension 14 (58.3 %) 13 (52.0 %)
Osteoporosis 5 (20.8 %) 5 (20.0 %)
Hypercholesterolemia 6 (25.0 %) –
Coxathrosis – 6 (24.0 %)
Gonarthrosis – 6 (24.0 %)
Spondylosis – 15 (60.0 %)
Qualitative data are expressed as number (%) and quantitative data as
mean ± standard deviation or median (1st–3rd interquartile), as
appropriate
aMCV anti mutated citrullinate vimentin, CRP C reactive protein,
DAS-28 disease activity score, ESR erythrocyte sedimentation rate,
RA rheumatoid arthritis, RF rheumatoid factor
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Discussion
In this study characteristic alterations were demonstrated in
TG parameters of RA patients compared to those in the
control subjects. The majority of routine tests of hemostasis
(except for fibrinogen level) were normal in RA.
CAT measurement as a global haemostasis assay for the
assessment of TG provides a comprehensive tool for the
assessment of functional state of the haemostatic system; it
reflects the contribution of both pro- and anticoagulant
processes to the haemostatic balance. As a result CAT can
be considered a more sensitive method than routine coag-
ulation tests to describe the thrombotic state of patients in
complex haemostatic alterations such as chronic systemic
inflammation in RA.
Among the 5 measured CAT parameters (ETP, Peak,
Lag Time, Time to Peak, v index) 4 differed significantly
in RA from those in the control group. The characteristics
of CAT curve was not clearly specific for thrombophilia or
haemophilia, as its parameters shared a mixed pattern:
kinetic CAT parameters (i.e. reduced Lag Time and Time
to Peak and increased v index) suggested an increase in
general thrombotic tendency, while reduced ETP indicated
an impaired thrombotic potential. Typical examples for TG
curves of a RA patient and a control subject are represented
on Fig. 2. The net effect of these changes, however, was an
earlier and accelerated formation of reduced amount of
thrombin. These changes were associated with RA activity
(i.e. DAS-28 scores).
The mutual relationship between inflammation and
coagulation is well established. While inflammatory
mechanisms shift haemostatic balance towards increased
coagulation, coagulation processes can enhance inflam-
matory response [reviewed in 5, 13]. Inflammation pro-
motes procoagulation and downregulates anticoagulant
processes by increasing platelet count and reactivity, ele-
vating fibrinogen and CRP concentrations, inducing
expression of protease activated receptors on endothelium,
and tissue factor expression on cell surface of leucocytes.
(Indeed, in RA patients the determined fibrinogen levels
correlated with CRP levels and DAS-28.) Elevated CRP
level promotes interactions of monocytes and endothelial
cells [14], and formation of plasminogen activator inhi-
bitor-1 [15] and that of tissue factor [16]. Inflammatory
mediators affect anticoagulant pathways by the downreg-
ulation of thrombomodulin and endothelial protein C
Table 2 Comparison of standard coagulation tests and CAT parameters of rheumatoid arthritis (RA) and control group, and that of patients on
DMARD—biologic therapy and those receiving DMARDs only
RA Control p
RA versus
control
Biologic
agents?
Biologic agents- p
Biologic agents? versus
biologic agents-
Number 24 25 10 14
PT (INR) 1.05 ± 0.05 1.06 ± 0.05 ns. 1.05 ± 0.04 1.03 (1.00–1.09) ns.
aPTT (s) 35.3 (33.9–39.8) 34.3 ± 3.3 ns. 38.1 ± 5.9 34.7 (33.6–36.7) ns.
TT (s) 18.8 ± 1.2 17.7 ± 1.2 0.003 18.7 ± 1.2 18.8 (18.1–19.2) ns.
Fibrinogen (g/l) 3.29 ± 0.56 3.09 ± 0.51 ns. 3.13 ± 0.57 3.41 ± 0.55 ns.
ETP (nM min) 1108 ± 168 1242 ± 186 0.012 1157 ± 196 1074 ± 142 ns.
Peak (nM) 236 ± 44 209 ± 60 ns. 234 ± 53 226 (208–238) ns.
Lag Time (min) 2.83 (2.67–3.25) 3.47 ± 0.91 0.039 2.72 ± 0.33 3.12 ± 0.69 ns.
Time to Peak (min) 5.58 ± 0.79 6.98 ± 1.67 0.001 5.35 ± 0.70 5.74 ± 0.83 ns.
v index (nM/min) 83 (72–121) 60 (35-104) 0.017 98 ± 35 79 (73–106) ns.
Data with normal distribution are expressed as mean ± standard deviation and in case of non-normal distribution as median (1st-3rd
interquartile)
Significant differences are marked with bold letters
aPTT activated partial thromboplastin time, ETP endogenous thrombin potential, INR international normalised ratio, PT prothrombin time, TT
thrombin time, v index Velocity Index
Fig. 2 Typical thrombin generation curve of a rheumatoid arthritis
(RA) patient (solid line) and that of a control subject (dashed line). In
RA Endogenous Thrombin Potential, Lag Time and Time to Peak is
decreased, while Velocity Index is increased
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receptor, thus diminishing protein C activation. In inflam-
mation, lowered antithrombin level can be caused by
reduced synthesis, degradation and consumption and the
decreased synthesis of glycosaminoglycans. Lowered
antithrombin activity results in delayed inhibition of the
coagulation enzymes that favours thrombotic tendency.
Our observations are not fully in line with the results
obtained in a recent study of Undas et al. [11]. This team
analysed the TG profile of RA patients calculated with a
computational model from their plasma composition. They
found that compared to control group RA patients had
significantly higher Peak and v index, and prolonged Lag
Time and Time to Peak. In contrary to our results, these
data indicate delayed but augmented thrombin burst in
patient samples.
These contradictions are probably due to different study
design, populations tested and methods used. Firstly, there
are numerous differences in patient and control group
selection. In the previous study the investigated population
was heterogeneous in term of age, disease duration and
gender, and control group consisted of healthy subjects.
Our study focused on the TG profile of postmenopausal RA
women, a specific subpopulation, and—to avoid the bias
inherent with the use of different age-group—we enrolled
age-matched control subjects with a comparable overall
health status (without RA). Secondly, Undas et al. deter-
mined the TG profile by kinetic modelling, while we
measured them empirically. Despite the advances of the
kinetic modelling of TG, the limitations of computational
modelling should be considered when calculated results are
compared to measured parameters [17].
When evaluating the results of our study one should con-
sider that each RA patient participating received DMARD
agents combined with or without biological therapy. Theo-
retically, these agents may also influence directly (through
their impact on pro- and anticoagulation factors) and indi-
rectly (through their anti-inflammatory action) the
haemostasis. We speculate that these drugs may be responsi-
ble that ETP and TT values in our RA patients were incon-
sistent with kinetic CAT results (they indicated an impairment
in TG in RA). The detailed analysis of association between
coagulation parameters, CAT parameters and drugs used
excluded the contribution of biological therapies to observed
alterations. (Literary data support no significant impact of
biological agents on thrombotic tendency either [12].)
However, as nearly all RA patients (22/24) were given
DMARD for several years, the modulatory effect of
DMARD in coagulation system in RA cannot be excluded.
Indeed, Undas et al. [11] demonstrated that patients taking
methotrexate (a DMARD) had decreased thrombotic ten-
dency. In our population with chronic RA requiring con-
tinuous DMARD therapy the possible impact of DMARD
agents, therefore, cannot be excluded.
One should also note that our results characterize
coagulation in a specific RA subpopulation homogeneous
in term of gender (women) and age (postmenopause) and
the long term duration of the disease. RA, however, may
also affect men and patients of other ages. The possibility
that haemostatic conditions in other RA subpopulation are
different cannot be excluded and should be the subject for
further studies including patients with higher disease
activity or patients with early RA.
In conclusion, to our knowledge, we are the first to
perform CAT measurements in a homogenous RA popu-
lation. Our results indicate earlier and accelerated forma-
tion of a reduced amount of thrombin. This suggests that
RA is associated with alterations of the haemostatic system
in a way that it is prepared for fast response to provoking
stimuli, thus the haemostatic balance is altered towards
thrombotic tendency, but impaired thrombin amount
counterbalance this feature.
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